Biotech News
Related news
MNKDMannKind2026-05-29 16:30 EST
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MNKDMannKind2026-07-24 10:30 EST
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
TERNTerns Pharmaceuticals2026-04-27 12:05 EST
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
VANIVivani Medical2026-06-25 11:30 EST
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
SGMTSagimet Biosciences2026-08-13 11:00 EST
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
RYTMRhythm Pharmaceuticals2026-05-01 10:55 EST
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
ALGSAligos Therapeutics2026-04-14 20:05 EST
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
RYTMRhythm Pharmaceuticals2026-08-24 12:00 EST
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
VKTXViking Therapeutics2026-06-11 11:05 EST
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
CVRXCVRx2026-08-24 12:30 EST
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-07-29 10:30 EST
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MNKDMannKind2026-07-28 20:01 EST
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MNKDMannKind2026-07-24 10:35 EST
MannKind Announces $50 Million Private Placement
MNKDMannKind2026-07-24 10:30 EST
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
Stock data
- Close
- 4.15 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States